Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
August 04, 2022 08:00 ET
|
Replimune Group Inc
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data...
Replimune to Present at Two Upcoming Investor Conferences
August 01, 2022 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
June 03, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 17:15 ET
|
Replimune Group Inc
WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
May 19, 2022 08:00 ET
|
Replimune Group Inc
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first...
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
March 30, 2022 07:00 ET
|
Replimune Group Inc
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with...
Replimune to Host Virtual Investor Event on March 30, 2022
March 21, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
February 03, 2022 08:00 ET
|
Replimune Group Inc
Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed...